EP3684506A1 - Récipient portable pour pré-analyse de la tuberculose - Google Patents

Récipient portable pour pré-analyse de la tuberculose

Info

Publication number
EP3684506A1
EP3684506A1 EP18769691.9A EP18769691A EP3684506A1 EP 3684506 A1 EP3684506 A1 EP 3684506A1 EP 18769691 A EP18769691 A EP 18769691A EP 3684506 A1 EP3684506 A1 EP 3684506A1
Authority
EP
European Patent Office
Prior art keywords
fluid channel
sample material
lid
main body
connection port
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18769691.9A
Other languages
German (de)
English (en)
Inventor
Gerhard Hartwich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Friz Biochem Gesellschaft fuer Bioanalytik mbH
Original Assignee
Friz Biochem Gesellschaft fuer Bioanalytik mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friz Biochem Gesellschaft fuer Bioanalytik mbH filed Critical Friz Biochem Gesellschaft fuer Bioanalytik mbH
Publication of EP3684506A1 publication Critical patent/EP3684506A1/fr
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082—Test tubes per se
    • B01L3/50825—Closing or opening means, corks, bungs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/56—Labware specially adapted for transferring fluids
    • B01L3/563—Joints or fittings ; Separable fluid transfer means to transfer fluids between at least two containers, e.g. connectors
    • B01L3/5635—Joints or fittings ; Separable fluid transfer means to transfer fluids between at least two containers, e.g. connectors connecting two containers face to face, e.g. comprising a filter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02—Adapting objects or devices to another
    • B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/04—Closures and closing means
    • B01L2300/041—Connecting closures to device or container
    • B01L2300/042—Caps; Plugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/04—Closures and closing means
    • B01L2300/046—Function or devices integrated in the closure
    • B01L2300/047—Additional chamber, reservoir
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter

Definitions

  • the invention relates to a portable container, in particular for tuberculosis preanalytics, and to a method for pretreating a sample material to be analyzed with such a portable container.
  • Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and more rarely Mycobacterium bovis or other close relatives of the so-called Mycobacterium tuberculosis complex (MTC) such as the less pathogenic strains M. africanum, M. microti and M. canetti is triggered.
  • MTC Mycobacterium tuberculosis complex
  • Tuberculosis leads the world in the statistics of deadly infectious diseases.
  • the incidence of the infectious disease is very unevenly distributed worldwide: in 2015, 60% of cases occurred in only six countries: India, Indonesia, China, Nigeria, Pakistan and South Africa.
  • the treatment of tuberculosis is carried out with a multiple combination of antibiotics, called tuberculostatic drugs, over several months.
  • the tuberculosis therapy is flanked by the co-treatment of possibly accompanying comorbidities, which cause an immunodeficiency. To clarify suspected TB, reliable diagnostic procedures are needed.
  • the result must also be available as soon as possible, so that appropriate treatment can be started as early as possible. If pulmonary tuberculosis is suspected, a microscopic examination for acid-fast rods (Ziehl-Neelsen staining) should always be performed to clarify the infectivity. However, about 10 4 germs / ml must be present in order to obtain a positive result, so that up to 50% false-negative results must be expected. In HIV-positive individuals, the false-negative proportion may be even higher.
  • the gold standard in the TB diagnosis is the culture:
  • the test material is first decontaminated with N-acetyl-L-cysteine-NaOH, then the material is centrifuged and the sediment is placed on nutrient media.
  • a typical nutrient medium is e.g.
  • mycobacteria convert an admixed fumeless terazolium salt into water-insoluble pink to violet formazan via the redox system; Flask of liquid culture indicates mycobacteria, as other germs are suppressed by the nutrient medium and the antibiotic mixture PACT (polymyxin B, amphotericin B, carberdcillin, trimethoprim).
  • tuberculosis bacteria (16 to 20 h) on solid media requires a very long growing time of 6 to 12 weeks, it can be shortened to about two weeks by using a liquid medium. Sensitivity is high for liquid media (about 10 bacteria / ml) and slightly better than for solid media (about 100 bacteria / ml). However, liquid media do not permit visual assessment of the colonies and thus no species diagnosis / subtyping of the mycobacteria. In the case of liquid media, this must be done independently by probe hybridization / genotyping in order to ensure specific detection of mycobacteria of M. tuberculosis. culott complex and possible differentiation of the M. tuberculosis complex in M. tuberculosis, M.
  • the therapy takes place as antibiotic combination therapy;
  • First-line antibiotics are isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and ethambutol (EMB) or streptomycin (second-line drugs are prothionamide and capreomycin).
  • IH isoniazid
  • RAF rifampicin
  • PZA pyrazinamide
  • EMB ethambutol
  • streptomycin second-line drugs are prothionamide and capreomycin.
  • the combination therapy recommended by the WHO may also fail: the increased incidence of bacterial resistance has made the treatment of tuberculosis much more difficult in recent years.
  • the trigger is the incorrect or uncontrolled use of the available tuberculostatics.
  • tuberculosis special forms of tuberculosis. These include multidrug-resistant tuberculosis (MDR-TB), which is resistant to at least one of the first-line drugs INH or RIF, and extremely drug-resistant tuberculosis (XDR-TB), which is resistant to at least one of the first-line Drugs INH or RIF, second line drugs based on fluoroquinoline and at least one of the injectable secondary line drugs capreomycin, kanamycin or amikacin.
  • MDR-TB multidrug-resistant tuberculosis
  • XDR-TB extremely drug-resistant tuberculosis
  • Treatment of MDR-TB and XDR-TB disorders is costly and may take more than 24 months. In some cases of XDR-TB, even no drug option is available.
  • the complexity and duration of culture-based MTB diagnostics and the modern laboratory infrastructural requirements of PCR techniques represent a previously unresolved problem, especially in countries where TB is most prevalent Targeted immediate treatment of infection and the suppression of further spread of MDR and XDR TB are urgently needed, even in countries / regions with state-of-the-art infrastructure, which are time-consuming and cost-intensive. Cost-effective, fast, but also easy-to-perform test systems are therefore urgently needed.
  • the PCR based test system Xpert MTB / RIF introduces a first, easy-to-use and (expensive) automated device with a dedicated test system that can detect TB diagnosis and associated resistance in a relatively short time.
  • a cartridge for carrying out a chemical reaction comprising a body with at least a first and a second channel formed therein, wherein the cartridge further comprises a reaction vessel extending from the body with a reaction chamber; an inlet port connected to the reaction chamber via an inlet port; and an outlet port connected to the reaction chamber via an outlet channel, the inlet port of the vessel being connected to the first channel in the body and the outlet port of the vessel being connected to the second channel in the body.
  • the invention provides a portable container, in particular for tuberculosis preanalytics, having a cup-shaped main body with a bottom, side walls and an upper opening, wherein a receiving area for the sample material to be analyzed, in particular sputum, is provided in the bottom area of the main body, a lid for closing the upper opening of the main body, with an in the closed position facing the container interior underside and an outwardly facing top, and a lid from the top to the bottom and penetrating the receiving area leading fluid channel, the
  • the lid top having an external connection port for an external supply device for supplying a pretreatment solution for the pretreatment of the sample material in the receiving area, and a collection filter for collecting components of the sample material pretreated in the container.
  • the fluid idkanal on the bottom cover has an inner connection port for later connection to an external analysis device for analyzing the collected in the collection filter components of the sample material, and that the collection filter in the fluid channel between the outer and the inner connection terminal.
  • the fluid channel preferably has adjacent to the inner connection port a predetermined breaking point for the separation of a (relative to the connection point with the lid) distal fluid channel section.
  • the outer and / or inner connection connection is preferably a Luer connection.
  • a mechanical solubilization aid to be provided in the receiving area of the main body in an original area.
  • chemicals for a pretreatment step of the sample material may also be initially introduced into the template region and may advantageously be immobilized there.
  • the template area is completed with advantage by a destructible when closing the main body cover layer.
  • the fluid channel is formed in an advantageous embodiment by a Fluidrschreib- Chen, which is detachably mounted in the lid.
  • the invention also includes a method for pretreating a sample material to be analyzed, in particular sputum, with a portable container of the type described, in which a) the cup-shaped main body is closed after introduction of sample material to be analyzed with the lid, so that the lid underside ins B) a supply device, in particular a syringe, connected to the outer connection port of the fluid channel of the lid and a pretreatment solution is supplied via the fluid channel to the receiving region, and c) the pretreated sample material via the fluid channel again in the external delivery device is aspirated, whereby components of the pretreated sample material are collected in the collection filter.
  • the sample material is decomposed according to current understanding in different sized components, the TB exciters are indeed inactivated due to their high stability, but their mechanical structure remains largely intact, while the other cell material is dissolved.
  • the mycobacteria can therefore be separated from the cell components of the other lysed bacteria and organisms with a suitable collection filter 44.
  • the pretreatment solution serves in particular for the decontamination of the sample material, in which fast-growing organisms / bacteria are killed and Mycobacterium tuberculosis bacilli are selected.
  • the selection is based on killing / lysing the other (human) cell material with chemicals that leave the cells of the mycobacteria untouched due to the high stability / impermeability of the mycobacterial cell wall.
  • mycobacteria show an increased tolerance to alkalis, acids, detergents such as SDS or Triton X-100 or Tween20 and to enzymatic lysis methods such as the use of lysozyme.
  • different protocols have been developed, which can be used in particular in the pretreatment solutions mentioned in this application.
  • N-acetyl-L-cysteine (NALC) -NaOH method is used most universally: By alkaline lysis with NaOH we kill a variety of bacteria and organisms, the mycobacteria but hardly attacked. At the same time, the mucolytic N-acetyl-L-cysteine ensures solubilization of the sputum. As a result, optionally inactivated, but otherwise intact mycobacterial cells can be separated, for example via sterile filtration, from the remaining cell constituents of the remaining lysed bacteria and organisms.
  • the sputum is incubated with a decontamination solution of 2% NaOH (0.5N NaOH) and 0.25% NALC for 15 min at RT.
  • the mycobacterial material can also be disinfected and inactivated because the mycobacteria must be killed as a biological safety measure for molecular diagnostics. This can be done by heat inactivation at T ⁇ 80 ° C for t ⁇ 20 min, or also by means of a pretreatment solution by an approximately 3 minute alcoholic disinfection with 70% isopropanol / n-propanol or 80% ethanol.
  • the beaker is connected via the external connection connection to an analysis device for analyzing the components of the sample material collected in the collection filter.
  • the fluid channel is connected to the internal connection port with an analysis device for analyzing the components of the sample material collected in the collection filter.
  • an analysis device for analyzing the components of the sample material collected in the collection filter.
  • a distal fluid channel section at the predetermined breaking point is preferably separated from the fluid channel in order to make the inner connection port accessible, and the remaining fluid channel is connected to the analysis device with the inner connection port.
  • the further purification, amplification and detection of any mycobacteria collected in the collection filter takes place in the analysis device as a back-end module and is not the subject of the present invention.
  • the proposed portable container provides a front-end tool for tuberculosis preanalytics from sample collection to isolation Essentials of whole but inactive / non-infectious / non-proliferative mycobacterial cells. In particular, it enables the following steps for improved molecular diagnosis of TB:
  • FIG. 1 schematically shows a pre-analytic cup with lid after a
  • FIG. 1 shows a preanalytical cup 10 with lid 30, which, for illustration, is shown slightly offset from the cup-shaped main body 12 of the cup 10 in a position shortly before the cup is completely closed.
  • the cup-shaped main body 12 has a bottom 14, side walls 16 and an upper opening 18, which can be closed with the lid 30.
  • a mechanical solubilization aid 24, for example in the form of small stones, as well as immobilized chemicals 26 for a pretreatment step of the sample material P are presented in a presentation area 22.
  • the original region 22 is closed by a cover layer 28, which can be destroyed when the main body 12 is closed, in the form of a thin plastic film.
  • the cover 30 has an upper side 32 and a lower side 34, wherein the lower side 34 points in the closed position indicated in FIG. 1 into the interior of the cup 10.
  • a fluid channel 36 penetrates the lid 30 from the top 32 to the bottom 34 and extends in the closed position into the receiving area 20 of the cup 10.
  • the fluid channel 36 is formed by a releasably fixed in a central opening of the lid 30 tube whose length is dimensioned so that in the closed position of the lid 30 with a lower tube portion 38, the cover layer 28 pierces and thus exposes the mechanical solubilization aid 24 and the chemicals 26.
  • the fluid channel 36 includes two Luer connection ports pointing in opposite directions, namely an outer Luer connection 40 on the cover top 32 and an inner Luer connection 42 on the cover bottom 34.
  • the inner Luer connection 42 is initially still inaccessible in the interior of the fluid channel 36th as shown in Fig. 1.
  • a collection filter 44 is arranged in the fluid passage 36 for collecting components of the sample material P pretreated in the container.
  • the external luer connection 40 serves to connect an external supply device 100 for supplying a pretreatment solution 102 for the pretreatment of the sample material P, as explained in greater detail below.
  • the inner luer fitting 40 is provided for later connection to an external analysis device 200 (FIG. 2) for analyzing the components of the sample material P collected in the collection filter 44. Since it is initially inaccessible in the interior of the fluid channel 36, a predetermined breaking point 46 in the tube is provided directly adjacent to separate the lower fluid channel section 38.
  • a workstation for the laboratory-independent preanalytics with the cup 10 of FIG. 1 can, for example, proceed as follows:
  • a sputum obtained as a sample material P from a patient suspected of having pulmonary tuberculosis is placed in the receiving area 20 of the cup 10, and the cup-shaped main body 12 is closed with the lid 30.
  • These steps can be performed by the patient himself and therefore do not pose an infection risk for the examiner.
  • the tube 36 pierces the cover layer 28 with its lower portion 38 and thus exposes the chemicals 26 and the solubilization aid 24.
  • a syringe 100 or other delivery device is connected to the outer luer fitting 40 of the fluid channel 36 and a suitable pretreatment solution 102 is introduced via the fluid channel 36 into the
  • the sample material P is solubilized and decontaminated and optionally also inactivated.
  • This step may be performed by the patient or an examiner, and in addition to supplying the pretreatment solution 102 requires only mechanical shaking of the mixture in the sealed cup.
  • the pretreated, namely solubilized, decontaminated and optionally also inactivated sample material is sucked out of the receiving region 20 via the fluid channel 36 through the collecting filter 44 back into the syringe 100.
  • the other cell material is lysed, so that essentially only the stable cells of the mycobacteria 50 (FIG. 2) are collected in the collection filter 44.
  • These have a special cell wall structure with high lipid and wax content, which is responsible for the high resistance and stability of the bacilli.
  • the tube 36 can now be detached from the cover 30 by an examiner by separating the lower section 38 of the fluid channel 36 at the predetermined breaking point 46, so that the inner tube connection 42 becomes accessible.
  • the cells of the mycobacteria 50 collected in the case of infection are present on the side of the collection filter 44 facing the inner Luer connection 42. Now, if necessary after prior cleaning of the collected material in the collection filter 44, the remaining stump 52 is connected via the inner Luer connection 42 with an analysis device 200 for analyzing the collected in the collection filter 44 components of the sample material.
  • the following methods for the purification, amplification and detection of the mycobacteria 50 in the analysis device 200 are not the subject of the present invention.
  • some of the elements described in connection with FIG. 1 may also be dispensed with.
  • the chemicals 26 and optionally also the solubilization aid 24 may be dispensed with.
  • Their func- For example, it may be partially or completely taken over by the pretreatment solution (s) supplied via the external connection port 40.
  • the pretreatment solution supplied via the external connection port 40.
  • the syringe 100 there may be a layered pretreatment solution which successively enables decontamination and inactivation of the sample material.
  • the inner connection port 42 of the fluid channel 36 is dispensed with.
  • the fluid channel 36 is connected with its external connection port 40 to an analyzer device 200.
  • the lid 30 does not have to be removed from the main body 12, so that, for example, a rinsing solution for cleaning the collected in the collection filter 44 material from the cup 10 can be added.
  • care must be taken to ensure that, on the one hand, the bacilli collected on the filter are not flushed back into the beaker and, on the other hand, that the TB-DNA does not or only slightly diffuse into these flushing fluids in the fluid channel after disruption of the TB cells can be more introduced into the analysis device 200.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un récipient portable (10), destiné en particulier à la pré-analyse de la tuberculose. Le récipient portable comprend - un corps principal (12) en forme de coupe pourvu d'un fond (14), de parois latérales (16) et d'une ouverture supérieure (18), une région de réception (20) destinée au matériau échantillon (P) à analyser, en particulier des expectorations, étant prévue dans la région de fond du corps principal (12), - un couvercle (30) destiné à fermer l'ouverture supérieure (18) du corps principal (12), un côté inférieur (34) tourné vers l'intérieur du récipient dans la position fermée et un côté supérieur (32) tourné vers l'extérieur, et - un conduit de fluide (36) qui traverse le couvercle (30) depuis le côté supérieur (32) vers le côté inférieur (34), qui mène à la région de réception, et qui comporte - sur le côté supérieur (32) du couvercle un raccord de connexion extérieur (40) destiné à un moyen d'amenée extérieur (100) destiné à amener une solution de prétraitement (102) destinée au prétraitement du matériau échantillon (P) dans la région de réception (20), et - qui comporte un filtre de collecte (44) destiné à collecter les constituants du matériau échantillon prétraité dans le récipient.
EP18769691.9A 2017-09-22 2018-09-14 Récipient portable pour pré-analyse de la tuberculose Pending EP3684506A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017008908.6A DE102017008908A1 (de) 2017-09-22 2017-09-22 Tragbarer Behälter für die Tuberkulose-Präanalytik
PCT/EP2018/074852 WO2019057620A1 (fr) 2017-09-22 2018-09-14 Récipient portable pour pré-analyse de la tuberculose

Publications (1)

Publication Number Publication Date
EP3684506A1 true EP3684506A1 (fr) 2020-07-29

Family

ID=63586731

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18769691.9A Pending EP3684506A1 (fr) 2017-09-22 2018-09-14 Récipient portable pour pré-analyse de la tuberculose

Country Status (3)

Country Link
EP (1) EP3684506A1 (fr)
DE (1) DE102017008908A1 (fr)
WO (1) WO2019057620A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111366409A (zh) * 2019-11-15 2020-07-03 浦洪杰 一种笔刷的取样涂片方法及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429803A (en) * 1991-04-18 1995-07-04 Lamina, Inc. Liquid specimen container and attachable testing modules
WO1999033559A1 (fr) 1997-12-24 1999-07-08 Cepheid Cartouche de manipulation de fluide integree
US20160054202A1 (en) * 2004-08-04 2016-02-25 Infinite Medical Technology Corp. Diurnal urine collection system
US7648681B2 (en) * 2004-12-01 2010-01-19 Meridian Bioscience, Inc. Specimen collection system
DE102013012353B4 (de) * 2012-08-06 2021-08-05 lege artis Pharma GmbH & Co. KG System zur Entnahme medizinischer Flüssigkeiten aus Behältern
US11454570B2 (en) * 2016-02-29 2022-09-27 Distek, Inc. Sample probe for dissolution testing and the like

Also Published As

Publication number Publication date
WO2019057620A1 (fr) 2019-03-28
DE102017008908A1 (de) 2019-03-28

Similar Documents

Publication Publication Date Title
EP3328987B1 (fr) Dispositif et procédé de traitement de liquides, notamment de liquides corporels
DE69429783T2 (de) Vorrichtung und verfahren zur sammlung von zellen aus einer flüssigen probe
DE2021558C3 (de) Verfahren zur Durchführung mikrobiologischer, immunologischer, klinisch-chemischer o.ä. Untersuchungen und Vorrichtung zur Durchführung des Verfahrens
EP0995097B1 (fr) Dispositif et procede d'isolation de matiere cellulaire dans une enveloppe tissulaire et/ou un liquide
DE69331878T2 (de) Verfahren und vorrichtung zur gewinnung einlagiger zellkulturen
WO2002003058A2 (fr) Dispositif et procede pour mettre en contact electrique des cellules biologiques en suspension dans un liquide
DE102010033105A1 (de) Massenspektrometrische Sepsisdiagnose ohne Blutkultur
DE69032171T2 (de) Verfahren und Gerät zur Untersuchung von MAI (Myocobacterium Avium-Intracellulare) auf Antibiotikumsensitivität
DE69720248T2 (de) Schneller mikrobieller test
EP0088971A2 (fr) Dispositif pour la détection de bactéries, de champignons et de virus dans le sang
EP3684506A1 (fr) Récipient portable pour pré-analyse de la tuberculose
DE102008047240B4 (de) Verfahren zur Identifikation von Einzelviren in einer Probe
EP0734768A1 (fr) Procédé de fixation d'une substance biologique
EP2279264B1 (fr) Procédé de caractérisation de l'activité biologique d'oeufs de trichuris
EP2880147B1 (fr) Dispositif et procédé de traitement d'un milieu de filtration
DE102017124840B3 (de) Inkubator, Probenbehälter, Set und Verfahren zur Untersuchung eines Probenmaterials
DE102013109065B4 (de) Anordnung zum schnellen Diagnostizieren der Tuberkulose und zum Testen der pharmazeutischen Wirkung
DE212021000370U1 (de) Robotermechanismuseinheit zur Verwendung bei in vitro Diagnosetests und -analysen
DE102018131696A1 (de) Verfahren für die Analyse einer Blutprobe eines Menschen auf eine Tuberkuloseerkrankung
DE102014208748B4 (de) Multifunktionales Einwegbehältnis und Verwendung desselben für eine Zubereitung und Verteilung von mikrobiologischen Lösungen
DE19950341C1 (de) Vorrichtung zum Abscheiden von Mikroorganismen aus Mikroorganismen-enthaltenden Gasen und ihre Verwendung
DE102019122467B4 (de) Verfahren zur Durchführung von in vitro-Freisetzungsstudien
DE202012007324U1 (de) Vorrichtung zur Behandlung eines Filtrationsmediums
DE102022115561B4 (de) Massenspektrometrische Bestimmung der Zelltoxizität
Tomaso et al. Einsatzrelevanz der PCR als diagnostisches Verfahren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FRIZ BIOCHEM GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231222